Biotechnology in the Heart of the Capital City

CSL Behring is a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases. Our treatments offer promise for people in more than 100 countries.

Find our more about our company

CSL Behring News

CSL Behring News

Government Officials Tour CSL Behring Bern 2

Government Officials Tour CSL Behring Bern

CSL Behring welcomes members of the canton and the Executive Council.

07 Mar 2025
RDD-2025_Beleuchtung

Bern lights up on Rare Disease Day

On 28 February, the Burgerspital Bern lit up in the colours of Rare Disease Day.

04 Mar 2025
ANDEMBRY logo

Approval for ANDEMBRY®

Swissmedic Approves CSL Behring’s ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (H…

26 Feb 2025
RDD-2025_EN

Rare are many

Bern lights up for Rare Disease Day

25 Feb 2025
SRF-Talk-CSLBehring-Bern

How CSL Behring in Bern Makes a Difference

Listen to the podcast episode from Echo der Zeit.

20 Feb 2025
HY Results EN 2025

Half Year Results 2024/2025

CSL reported net income after tax of $2.04 billion in the first half of 2025.

10 Feb 2025
WBB

Women Back to Business

A collaboration with the University of St. Gallen.

17 Oct 2024
EU Horizon Bio2Brain Summer School participants at CSL Behring Wankdorf

Commitment to young scientists

Highlighting career paths and providing insights into translational research was the aim of the EU Horizon Bio2Brain Summer S…

11 Sep 2024
FY2024_EN

Full Year Results 2024

CSL reports 15% profit growth with a full-year net profit of $2.91 billion (1,2).

13 Aug 2024
Load more